NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
List view / Grid view
The National Institute for Health and Care Excellence (NICE)
Filter the results
The National Institute for Health and Care Excellence is recommending MSD’s Prevymis (letermovir) within the NHS.